The phenomenon is highly significant clinically because it usually manifests itself in setting of chronic ischemia, which is potentially reversible by revascularisation. The regions of myocardium are still viable and can restore its function. There develops a new steady state between myocardial blood flow (MBF) and myocardial function, MBF reduced and in consequence function is reduced too. The clinical situations where one can expect hibernating myocardium are:
US Patent Issued to Amylin Pharmaceuticals, Astrazeneca Pharmaceuticals on Oct. 8 for "Treatment of Hibernating Myocardium with an Exendin Peptide" (Connecticut, Nebraska Inventors)
Oct 08, 2013; ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 8,551,947, issued on Oct. 8, was assigned to Amylin Pharmaceuticals LLC (San...